| Data Transparency Autumn Event 2024 – Registration now Open |
|---|
Active since 2014, PHUSE’s Data Transparency Working Group has provided subject matter expertise for the review of draft deliverables and guidance documents from regulatory bodies (such as the EMA and Health Canada), as well as other industry organisations (such as TransCelerate) and academia. Since their inception in 2020, the free-to-attend Data Transparency Events have gone from strength to strength. These virtual events have created an unrestricted space where questions can be asked and challenges addressed. Individuals passionate about the area can come together to share vital knowledge, develop new ideas and spark innovation through presentations, panel discussions and Q&A sessions alongside experts in the data-sharing field. The PHUSE Data Transparency Autumn Event will take place from 17–19 September 2024. Data Transparency Events offer you the chance to gain knowledge and experience from a wide data transparency community, allowing you to come together with experts from a variety of companies and backgrounds. During this virtual event, presentations will be delivered across the three days in bitesize chunks from 15:00-17:30 (BST). There will also be a panel discussion and Q&A session focused on the day's themes. Visit the PHUSE archive for all previous event recordings and presentations. |
| Agenda | |
|---|---|
| Presentation Title | Speaker(s) |
| Day 1 – 17 September | |
| Event-Based Access Control – Game Changer for Autonomous Security and Transparent Data Sharing | Amit Gautam, Abluva |
| Rare Disease Data – Overcoming Barriers to Controlled Access Sharing | Helen Spotswood, Roche & Karolina Stępniak, AstraZeneca |
| Optimising the Utility of Anonymised Data: A Clinical Case Study | Lisa Pilgram, University of Ottawa |
| Diversity in Clinical Trial Data Transparency: A New Horizon for Data Sharing with Truthful Statistics | Luk Arbuckle, Privacy Analytics & Stephen Bamford, Johnson & Johnson |
| Day 2 – 18 September | |
| Disclosure Without Exposure – Upstream Strategies for Enabling AI to Effectively and Efficiently Protect Clinical Data | Honz Slipka, Certara |
| Harnessing the Power of Artificial Intelligence (AI) in Accelerating Production of Clinical Documentation: A Case Study with Plain Language Summaries (PLS) | Kathi Künnemann, Staburo |
| De-Identification of Medical Data for AI Training, Speeding Up Clinical Trials, and Enabling Healthcare Research | Patricia Thaine, Private AI |
| Leveraging Agentic AI Networks to Automate Transparency Activities | Woo Song, Xogene |
| Day 3 – 19 September | |
| Privacy Methodology Implementation: Sharing Experience from the Field | Véronique Poinsot, Sanofi |
| True Re-Identification Risk Threshold – Aggregated-Level Clinical Information Impact on Anonymisation Methods Applied to Individual Patient-Level Data (IPLD) | Agnieszka Głowińska & Łukasz Szyszka, AstraZeneca |
| Writing Better CSRs to Facilitate Anonymisation for Clinical Data Publication | Cathal Gallagher & Laura Dodd, Instem |
| A Data Transparency Odyssey - A Decade of Data Sharing | Alex Hughes, Roche & Brent Caldwell, Novartis |
Data Transparency Autumn Event Sponsors |
|---|
Virtual Event Sponsors
|
Sponsor Flyers |
|
Sponsorship |
Hosting the Data Transparency Event digitally means that no matter where you are in the world you can participate. It provides the industry with a broader opportunity to share knowledge on a global scale, connecting through the virtual event platform. The sponsor options offer a range of benefits with ample company exposure. See the prospectus for more detail.
|
| Data Transparency Working Group Leads |
|---|
|
